13F Filings History of Commodore Capital LP
- Latest 13F filing
- Q1 2026 - 15 May 2026
- Latest reported 13F value
- $1,728,452,370
- Largest 13F holdings
-
RLAY ALKS ELVN COGT SYRE TYRA CLDX NUVL AMLX KYMR ANRO PHVS
+8 more
ERAS DMRA XENE DFTX LBRX EYPT NRIX CRVS - Form 13F summary
-
- Commodore Capital LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Commodore Capital LP reported 36 equity holdings with a total reported market value of $1,728,452,370 for Q1 2026. Top reported holdings included RLAY, ALKS, ELVN, COGT, and SYRE.
- Manager signature
- Michael Kramarz - Managing Partner
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Commodore Capital LP with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$1,728,452,370
Quarter delta
+$226,206,897
Accepted
15 May 2026, 16:36
Rows shown
1-22 of 22
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 36 | $1,728,452,370 | +$430,195,533 | -$466,248,965 | -$36,053,432 | RLAY, ALKS, ELVN, COGT, SYRE | 13F-HR | 15 May 2026, 16:36 |
| Q4 2025 | 33 | $1,502,245,473 | +$146,112,414 | -$1,292,601,361 | -$1,146,488,947 | RLAY, ALKS, TYRA, XENE, SYRE | 13F-HR | 17 Feb 2026, 16:05 |
| Q3 2025 | 37 | $2,048,436,266 | +$361,796,321 | -$229,917,294 | +$131,879,027 | MRUS, NUVL, XENE, COGT, ELVN | 13F-HR | 14 Nov 2025, 16:10 |
| Q2 2025 | 33 | $1,416,719,296 | +$328,166,413 | -$357,668,294 | -$29,501,881 | MRUS, NUVL, XENE, ELVN, AGIO | 13F-HR | 14 Aug 2025, 16:36 |
| Q1 2025 | 31 | $1,357,083,846 | +$292,196,506 | -$71,517,205 | +$220,679,301 | MRUS, NUVL, ELVN, SLNO, XENE | 13F-HR | 15 May 2025, 16:00 |
| Q4 2024 | 31 | $1,364,557,313 | +$305,311,153 | -$360,138,263 | -$54,827,110 | MRUS, PCVX, NUVL, XENE, ELVN | 13F-HR | 14 Feb 2025, 16:07 |
| Q3 2024 | 36 | $1,600,269,489 | +$182,219,512 | -$226,688,734 | -$44,469,222 | MRUS, VERA, XENE, PCVX, ELVN | 13F-HR | 14 Nov 2024, 15:45 |
| Q2 2024 | 35 | $1,465,008,171 | +$311,596,307 | -$248,255,919 | +$63,340,388 | MRUS, NUVL, XENE, PCVX, ELVN | 13F-HR | 14 Aug 2024, 16:25 |
| Q1 2024 | 39 | $1,495,487,511 | +$300,342,925 | -$296,302,110 | +$4,040,815 | MRUS, VERA, NUVL, XENE, SYRE | 13F-HR | 15 May 2024, 16:05 |
| Q4 2023 | 32 | $1,144,464,541 | +$264,504,596 | -$167,234,938 | +$97,269,658 | MRUS, XENE, NUVL, VERA, RYTM | Restatement | 14 Feb 2024, 16:38 |
| Q3 2023 | 30 | $855,509,177 | +$153,938,217 | -$119,541,865 | +$34,396,352 | MRUS, VERA, XENE, PCVX, COGT | 13F-HR | 14 Nov 2023, 16:00 |
| Q2 2023 | 26 | $889,839,183 | +$223,081,879 | -$132,878,612 | +$90,203,267 | MRUS, VERA, AKRO, XENE, COGT | 13F-HR | 14 Aug 2023, 16:00 |
| Q1 2023 | 32 | $656,834,859 | +$170,942,983 | -$107,374,156 | +$63,568,827 | XENE, VRDN, MRUS, COGT, BLU | 13F-HR | 15 May 2023, 16:06 |
| Q4 2022 | 35 | $663,544,000 | +$167,172,158 | -$118,388,162 | +$48,783,996 | XENE, VRDN, COGT, BLU, MRUS | 13F-HR | 14 Feb 2023, 11:00 |
| Q3 2022 | 30 | $601,204,702 | +$136,688,800 | -$59,662,237 | +$77,026,563 | COGT, XENE, VRDN, BLU, MRUS | 13F-HR | 14 Nov 2022, 16:00 |
| Q2 2022 | 24 | $453,358,635 | +$113,777,462 | -$50,517,323 | +$63,260,139 | MRUS, XENE, COGT, BLU, CYTK | 13F-HR | 15 Aug 2022, 17:02 |
| Q1 2022 | 27 | $447,722,000 | +$109,841,449 | -$46,296,761 | +$63,544,688 | MRUS, ACRS, BLU, ISEE, XENE | 13F-HR | 16 May 2022, 16:00 |
| Q4 2021 | 25 | $431,774,000 | +$131,307,231 | -$80,652,037 | +$50,655,194 | ISEE, MRUS, ACRS, XENE, CYTK | 13F-HR | 14 Feb 2022, 16:07 |
| Q3 2021 | 29 | $379,293,000 | +$137,271,143 | -$50,515,765 | +$86,755,378 | ISEE, ACRS, CYTK, DRNA, CCCC | 13F-HR | 15 Nov 2021, 16:02 |
| Q2 2021 | 29 | $287,021,000 | +$75,392,477 | -$45,829,699 | +$29,562,778 | ACRS, STSA, CELC, CCCC, CBAY | Restatement | 13 Oct 2021, 18:02 |
| Q1 2021 | 31 | $251,032,000 | +$74,305,186 | -$34,006,227 | +$40,298,959 | ACRS, CCCC, KURA, STSA, FPRX | Restatement | 13 Oct 2021, 17:58 |
| Q4 2020 | 28 | $183,931,000 | $0 | $0 | $0 | CCCC, TRILLIUM THERAPEUTICS INC, CNST, FPRX, KRON | 13F-HR | 16 Feb 2021, 16:13 |